Axsome Therapeutics (NASDAQ:AXSM – Free Report) had its goal worth lifted by Robert W. Baird from $112.00 to $116.00 in a analysis notice printed on Wednesday morning,Benzinga experiences. Robert W. Baird presently has an outperform score on the inventory.
A number of different equities analysis analysts have additionally issued experiences on the inventory. Needham & Firm LLC restated a “purchase” score and issued a $130.00 goal worth on shares of Axsome Therapeutics in a report on Tuesday, November twelfth. UBS Group dropped their goal worth on Axsome Therapeutics from $107.00 to $105.00 and set a “purchase” score for the corporate in a analysis report on Tuesday, August sixth. HC Wainwright reissued a “purchase” score and set a $180.00 worth goal on shares of Axsome Therapeutics in a analysis notice on Thursday, September fifth. Financial institution of America raised Axsome Therapeutics from a “impartial” score to a “purchase” score and upped their worth goal for the corporate from $95.00 to $106.00 in a analysis report on Tuesday, August sixth. Lastly, Cantor Fitzgerald reiterated an “chubby” score and set a $107.00 goal worth on shares of Axsome Therapeutics in a analysis report on Monday, September sixteenth. One equities analysis analyst has rated the inventory with a promote score and fourteen have assigned a purchase score to the corporate’s inventory. Based on information from MarketBeat, Axsome Therapeutics presently has a median score of “Average Purchase” and a median goal worth of $124.93.
Learn Our Newest Analysis Report on Axsome Therapeutics
Axsome Therapeutics Inventory Down 4.3 %
NASDAQ AXSM opened at $93.17 on Wednesday. The inventory has a 50 day transferring common worth of $90.66 and a 200-day transferring common worth of $84.35. Axsome Therapeutics has a one 12 months low of $56.66 and a one 12 months excessive of $105.00. The corporate has a market capitalization of $4.52 billion, a P/E ratio of -14.27 and a beta of 1.26. The corporate has a debt-to-equity ratio of 1.97, a fast ratio of two.40 and a present ratio of two.44.
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) final introduced its earnings outcomes on Tuesday, November twelfth. The corporate reported ($1.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.38) by $0.04. The agency had income of $104.76 million for the quarter, in comparison with analysts’ expectations of $98.71 million. Axsome Therapeutics had a damaging internet margin of 91.87% and a damaging return on fairness of 158.36%. Throughout the identical interval within the prior 12 months, the corporate earned ($1.32) EPS. As a bunch, equities analysts predict that Axsome Therapeutics will put up -5.04 EPS for the present fiscal 12 months.
Insider Exercise
In associated information, Director Mark E. Saad bought 11,016 shares of the enterprise’s inventory in a transaction that occurred on Wednesday, September eleventh. The shares had been bought at a median worth of $91.31, for a complete transaction of $1,005,870.96. Following the completion of the transaction, the director now owns 10,002 shares within the firm, valued at $913,282.62. The commerce was a 52.41 % lower of their place. The transaction was disclosed in a authorized submitting with the SEC, which is on the market by this hyperlink. Firm insiders personal 22.40% of the corporate’s inventory.
Institutional Buying and selling of Axsome Therapeutics
Numerous institutional traders have lately purchased and bought shares of the inventory. Sofinnova Investments Inc. acquired a brand new stake in shares of Axsome Therapeutics throughout the second quarter price about $24,971,000. Iron Triangle Companions LP acquired a brand new stake in Axsome Therapeutics throughout the third quarter valued at roughly $22,671,000. Tri Locum Companions LP boosted its holdings in shares of Axsome Therapeutics by 198.4% within the 2nd quarter. Tri Locum Companions LP now owns 306,513 shares of the corporate’s inventory valued at $24,674,000 after buying an extra 203,802 shares over the last quarter. FMR LLC elevated its stake in shares of Axsome Therapeutics by 20.6% within the third quarter. FMR LLC now owns 1,088,087 shares of the corporate’s inventory price $97,786,000 after buying an extra 185,951 shares throughout the interval. Lastly, Healthcare of Ontario Pension Plan Belief Fund acquired a brand new stake in shares of Axsome Therapeutics within the first quarter price $11,036,000. 81.49% of the inventory is presently owned by institutional traders and hedge funds.
About Axsome Therapeutics
Axsome Therapeutics, Inc, a biopharmaceutical firm, engages within the growth of novel therapies for central nervous system (CNS) issues in the US. The corporate’s business product portfolio consists of Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal exercise indicated for the remedy of main depressive dysfunction; and Sunosi (solriamfetol), a drugs indicated to the remedy of extreme daytime sleepiness in sufferers with narcolepsy or obstructive sleep apnea.
Learn Extra
Obtain Information & Rankings for Axsome Therapeutics Day by day – Enter your e-mail deal with under to obtain a concise each day abstract of the newest information and analysts’ scores for Axsome Therapeutics and associated corporations with MarketBeat.com’s FREE each day e-mail publication.
